IDEAYA Biosciences Inc. provided a business update outlining key corporate objectives for 2026. The company plans to advance four registrational trials, including IDE849, a Phase 1 DLL3 TOP1 ADC, as a monotherapy agent in neuroendocrine cancer, and darovasertib in both pre-metastatic and metastatic uveal melanoma. IDEAYA aims to submit an investigational new drug $(IND)$ application for a CDKN2A program by the end of 2026, which will enable combinations with IDE892 and IDE397 in MTAP-deleted cancers, and with IDE574, a dual KAT6/7 inhibitor. The company intends to initiate several Phase 1 trials in 2026, including IDE574 and IDE034, and begin a monotherapy registrational study for IDE849 in small cell lung cancer and neuroendocrine carcinomas by the end of 2026. Updated data from the Phase 1/2 IDE397 combination trial with Trodelvy in MTAP-deleted urothelial cancer will be presented at a medical conference in 2026. IDEAYA reported approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund its current operating plan into 2030. Commercial readiness activities for darovasertib are also advancing in the United States and globally in partnership with Servier.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009653), on January 12, 2026, and is solely responsible for the information contained therein.
